The global Large Granular Lymphocytic Leukemia (LGLL) Therapeutics Market size is expected to surpass an impressive valuation of USD 2,871.05 million in 2023 and is projected to reach USD 12,700 million by 2033, expand at a CAGR of 16.03%
The rise in the adoption of Natural killer cells for the treatment of cancer, infections, and liver diseases is a key factor that drives the growth of the Large Granular Lymphocytic Leukemia (LGLL) Therapeutics Market. In addition, Natural killer cells play a pivotal role in tumor immune surveillance, which boosts the adoption of Natural cell therapeutics across the globe. In addition, a rise in awareness among the population regarding various immunotherapies and an increase in research and development for the development of bi-specific antibodies for engaging Natural killer cells to eliminate tumor cells fuel the global market growth.
However, the dearth of specificity and poor in-vivo survival of the cells limit the Large Granular Lymphocytic Leukemia (LGLL) Therapeutics market growth. Furthermore, higher costs associated with the therapies and adverse side effects are anticipated to restrain market growth in the coming years. On the contrary, a significant surge in research and development activities toward the development of immunotherapy in developing economies is expected to offer profitable opportunities as per Large Granular Lymphocytic Leukemia (LGLL) Therapeutics Market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 2,871.05 million |
| Anticipated Forecast Value (2033) | USD 12,700 million |
| Projected Growth Rate (2023 to 2033) | CAGR 16.03% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market of Large granular lymphocytic leukemia therapeutics market was worth USD 1,670 million in 2018 while exhibiting a CAGR of 11.45% during the historical period. The recent increase in the number of approvals received for cancer immunotherapies is considered to have added value to the Large granular lymphocytic leukemia therapeutics market. Moreover, market players are making efforts the development of novel NK cell therapies which further gives a boost to the growth of this market.
For instance, Under the agreement, Gilead would receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001. DF7001 is a TriNKET designed to activate and direct NK and cytotoxic T-cell killing against cancer cells. The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth linked with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC).
Considering the above-mentioned factors and developments, the market for Large granular lymphocytic leukemia is projected to grow at a CAGR of 16.03% while reaching a market valuation of USD 12,700 million by end of the forecast period.
Adoption of Novel Therapies to Drive Market Growth
The introduction of novel therapy and rich promising pipeline drugs across the globe is anticipated to accelerate the market growth in the forecast period of 2023 to 2033. Furthermore, multiple treatment landscapes and a family history of leukemia therapeutics will further carve the way for the growth of the market.
The growing number of clinical trials and the increasing incidence and prevalence of cancer cases. Increasing demand for effective and advanced therapies has led to a growing Large Granular Lymphocytic Leukemia (LGLL) Therapeutics Market. Growing focus on research and development (R&D) is boosting the Large Granular Lymphocytic Leukemia (LGLL) Therapeutics Market and attracting investments from industry players like Amgen and Agios Pharmaceuticals Inc. Thus, augmenting the market growth.
High Cost of Treatment to restrain Market Growth
High treatment costs and concerns for the factors such as the lengthy process for the development and support of new cancer treatments are projected to restrain the market growth rate.
North America to dominate the market with Maximum Market Share
The market in North America is expected to garner a valuation of USD 6,667.5 million by end of the forecast period. This region is projected to account for a dominant share of 52.5% in the Large Granular Lymphocytic Leukemia (LGLL) therapeutics market due to the presence of a high incidence rate, and advancements in the treatment of leukemia. According to American Cancer Society estimates in January 2022, about 60,650 new cases of leukemia and 24,000 deaths from leukemia and there were around 11,450 deaths due to acute myeloid leukemia in the USA in the year 2022. The statistics involve a large percentage of the adult population and they require proper medical treatment to increase their life expectancy.
Also, beneficial government initiatives and a rise in the number of research partnerships are some of the drivers anticipated to drive market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly USD 17 million in research grants, to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.
On the other hand, in June 2021, Jazz Pharmaceuticals plc received United States Food and Drug Administration (FDA) approval for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. Thus, due to the above-mentioned developments, the market in this region is anticipated to witness robust growth.?
The market in South Asia will witness the fastest CAGR
The market in South Asia is expected to witness the fastest compound annual growth rate of 16.8% during the forecast period owing to increasing demand for Natural killer cells therapeutics to treat cancer. The market in this region is expected to hold a 16.2% market share with a valuation of USD 2,057.4 million by end of the forecast period.
The large Granular Lymphocytic Leukemia (LGLL) therapeutics market in this region comprises features such as an increasing need for better therapeutics options that will impair the manufacturers' launching new products into the market, enhancing its increased demand investment in research and development that will drive market growth.
Currently, various research studies are taking place, which are anticipated to create a competitive advantage for manufacturers to develop new and innovative natural killer (NK) cell therapeutics that will provide various other opportunities in the targeted market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Targeted therapy to dominate the market with maximum share
This segment is estimated to possess a 36.2% market share by end of the forecast period followed by chemotherapy. Owing to surging demand for targeted drugs, this segment is likely to dominate the market during the forecast period.
Targeted drugs are most widely used due to their fewer side effects and higher effectiveness and success rate as compared to chemotherapy. Due to these factors, its sales have increased in recent years and it will continue to retain its hegemony by 2033.
Chronic Myelogenous Leukemia accounts for the maximum share
Chronic Myelogenous leukemia is expected to dominate the market during the forecast period. This segment is expected to grow with a CAGR of 18.1% during the projected timeframe. It will lead the industry with a 39% market share by end of the forecast period. The rising prevalence of Chronic Myeloid Leukemia (CML) and the number of treatment options available for it are factors driving this market’s growth.
Additionally, the growth of this segment is driven by an aging population, increased financing for cancer research, and the creation of novel treatments. It is expected that a significant number of drugs will receive regulatory body approval throughout the projected period which will augment this segment’s growth.
The global large granular lymphocytic leukemia (LGLL) therapeutics market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Pfizer Inc., Merck KGaA, Novartis AG
Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 2,871.05 million |
| Market Value in 2033 | USD 12,700 million |
| Growth Rate | CAGR of 16.03% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug, Indication, Therapy, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Bristol Myers Squibb; Innate Pharma; Kymera Therapeutics; Takeda Pharmaceutical Company Limited; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG; AstraZeneca Plc.; Pfizer Inc.; Merck KGaA; Novartis AG |
| Customization | Available Upon Request |
The market is estimated to secure a valuation of USD 2.8 billion in 2023.
Bristol Myers Squibb and Innate Pharma are the top market players.
The market is anticipated to reach USD 12.7 billion by 2033.
An increase in the adoption of natural killer cells is expected to drive the market prospects.
Targeted Therapy segment is likely to remain preferred through 2033.
| Market Value for 2023 | USD 15,246.7 million |
|---|---|
| Projected Market Value for 2033 | USD 30,318.5 million |
| Value-based CAGR of Market for 2023 to 2033 | 7.1% |
| Market Estimated Size (2023) | USD 5,935.9 million |
|---|---|
| Market Forecasted Size (2033) | USD 15,735.3 million |
| Market CAGR (2023 to 2033) | 10.2% |
Explore Therapy Area Insights
View Reports
Large Granular Lymphocytic Leukemia (LGLL) Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
